Company Overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions. The company's products, which are sold throughout the world, have improved outcomes for more than ten million patients globally by reducing infection, itch, pain, scarring and harmful inflammatory responses. Sonoma's headquarters are in Boulder, Colorado, with manufacturing operations in Jalisco, Mexico. European marketing and sales are headquartered in Roermond, Netherlands.

Sonoma Pharmaceuticals and Medline Industries Launch New HOCl Wound Cleanser for U.S. Hospitals
Oct 14 2025, 8:30 AM EDT

Sonoma Pharmaceuticals Expands Market Reach with FDA Cosmetic Product Facility Registration and Microcyn-Based Cosmetic Product Listing Under MoCRA
Oct 7 2025, 8:30 AM EDT

Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Sep 25 2025, 4:01 PM EDT

Stock Overview

Symbol	SNOA
Exchange	Nasdaq
Market Cap	6.21m
Last Price	$3.78
52-Week	$1.75 - $6.9199

11/03/2025 09:00 PM EST

Investor Relations

T: 470-938-1011
ir@sonomapharma.com

Management Team

Amy Trombly
Chief Executive Officer

Jerry Dvonch
Chief Financial Officer

Sonoma Pharmaceuticals, Inc.
5445 Conestoga Court
Suite 150
Boulder, CO 80301

Disclaimer